(NASDAQ: PMVP) Pmv Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.
Pmv Pharmaceuticals's earnings in 2026 is -$77,742,000.On average, 6 Wall Street analysts forecast PMVP's earnings for 2026 to be -$77,924,908, with the lowest PMVP earnings forecast at -$86,233,627, and the highest PMVP earnings forecast at -$50,956,234. On average, 4 Wall Street analysts forecast PMVP's earnings for 2027 to be -$57,931,719, with the lowest PMVP earnings forecast at -$60,102,225, and the highest PMVP earnings forecast at -$54,875,944.
In 2028, PMVP is forecast to generate -$52,764,100 in earnings, with the lowest earnings forecast at -$50,694,920 and the highest earnings forecast at -$54,315,986.